Revenue ($USD) : $14,238,000,000
R&D spend : Not Available
Employees : 50,000
Fiscal year end : 9/30/2023
CEO : Tom Polen; Mike Garrison, EVP and medical president; Richard Byrd, EVP and interventional president

www.bd.com

Market disruptions in China appear to be creating some headwinds for BD, but company officials boasted of continued strong performance overall during the company’s third-quarter earnings announcement in early August. BD’s medical segment is enjoying increased market position in vascular access management and hypodermic products. Plus, medication management systems posted especially strong growth following a 510(k) clearance for its Alaris infusion pumps in 2023 that enabled U.S. distribution of the pumps to resume following a yearslong recall. Expect BD’s medical device industry footprint to grow even more now that it’s agreed to pay $4.2 billion to acquire Edwards Lifesciences‘ Critical Care business. Other important BD news includes its announcement early in 2024 that it would boost U.S. syringe production after the FDA issued warnings related to syringes made in China. –CN